Low-risk patients with mild hypertension derived no protective benefit from blood pressure drugs over 5.8 years of follow-up but had an increased risk of adverse effects potentially related to the medication, researchers reported in a new study.

The FDA has announced a Class I recall for 1.1 million packages of CoaguChek XS PT test strips used with point-of-care or in-home devices to adjust warfarin dosing.

Ischemic stroke patients—regardless of their individual characteristics or the severity of their stroke—are 20 percent more likely to be readmitted to the hospital within 30 days of discharge if they acquire any kind of infection during their initial stay, researchers reported Nov. 1 in Stroke.

Eight European scientific societies joined forces to produce what they say is the first interdisciplinary position paper to help clinicians manage patients with patent foramen ovales (PFOs).

Physicians successfully reversed the bleeding risk-treatment paradox in percutaneous coronary intervention (PCI) by prioritizing risk-concordant use of bleeding avoidance strategies like bivalirudin, radial access and vascular closure devices, according to a report published Oct. 31 in the Journal of the American Heart Association.

Researchers have discovered a novel biomarker in stable, ambulatory patients with heart failure with preserved ejection fraction (HFpEF), a finding which may lead to earlier diagnoses of HFpEF.

With the American Heart Association’s 2018 Scientific Sessions set for Nov. 10-12 in Chicago, two co-chairs of the programming committee previewed the themes of the meeting, its most anticipated clinical trials and the two new guidelines that will be unveiled.

ScieGen Pharmaceuticals has issued a recall of the blood pressure drug irbesartan after lab testing revealed a carcinogenic impurity, the FDA announced in a MedWatch Safety Alert.